Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Hendriks

Showing results (341-350 of 344) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 344 results.
ESMO Open|November 5, 2024
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapyV D de Jager, P Plomp, M S Paats, et al.
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2021
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 ConsortiumKarlijn de Joode, Jolien Tol, Paul Hamberg, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer GroupMariana Brandão, Elena Prisciandaro, Eleni Xenophontos, et al.
Pageof 35

Showing results (341-350 of 344) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 344 results.
ESMO Open|November 5, 2024
Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapyV D de Jager, P Plomp, M S Paats, et al.
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2021
Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 ConsortiumKarlijn de Joode, Jolien Tol, Paul Hamberg, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer GroupMariana Brandão, Elena Prisciandaro, Eleni Xenophontos, et al.
Pageof 35